-
Product Insights
NewPotassium Voltage Gated Channel Subfamily A Member 3 – Drugs In Development, 2024
The Potassium Voltage Gated Channel Subfamily A Member 3 pipeline drugs market research report outlays comprehensive information on the Potassium Voltage Gated Channel Subfamily A Member 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Immunology, Central Nervous System, Gastrointestinal, and Metabolic Disorders which include indications of Autoimmune Disorders, Rheumatoid Arthritis, Multiple Sclerosis, Parkinson's Disease, Inflammatory Bowel...
-
Product Insights
NewPotassium Voltage Gated Channel Subfamily KQT Member 2 – Drugs In Development, 2024
The Potassium Voltage Gated Channel Subfamily KQT Member 2 pipeline drugs market research report outlays comprehensive information on the Potassium Voltage Gated Channel Subfamily KQT Member 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Ear Nose Throat Disorders, and Cardiovascular which include indications of Epilepsy, Neuropathic Pain (Neuralgia), Tinnitus, Hearing Disorders, and Acute...
-
Product Insights
NewPotassium Voltage Gated Channel Subfamily KQT Member 3 – Drugs In Development, 2024
The Potassium Voltage Gated Channel Subfamily KQT Member 3 pipeline drugs market research report outlays comprehensive information on the Potassium Voltage Gated Channel Subfamily KQT Member 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, and Ear Nose Throat Disorders which include indications of Epilepsy, Neuropathic Pain (Neuralgia), Tinnitus, and Hearing Disorders. It also...
-
Product Insights
NewPotassium Voltage Gated Channel Subfamily KQT Member 4 – Drugs In Development, 2024
The Potassium Voltage Gated Channel Subfamily KQT Member 4 pipeline drugs market research report outlays comprehensive information on the Potassium Voltage Gated Channel Subfamily KQT Member 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Ear Nose Throat Disorders, and Central Nervous System which include indications of Hearing Disorders, Acute Sensorineural Hearing Loss, Amyotrophic Lateral Sclerosis, and...
-
Innovation Ranking
Innovation Ranking – Lions Gate Entertainment Corp
Lions Gate Entertainment Corp (Lionsgate) is a provider of entertainment services. It provides services such as motion picture production and distribution, television programming and series, home entertainment, international distribution and sales, games, music, and location-based entertainment. The company offers its services through the Starz network, OTT platforms, US multichannel video programming distributors, and STARZPLAY International services. It leases offices used by its network motion picture, television production, and media networks in India, the US, China, the UK, and Luxembourg. It...
-
Innovation Ranking
Innovation Ranking – Gates Industrial Corp plc
Gates Industrial Corp plc (Gates) is a power transmission and fluid power solutions-based manufacturing company. It offers a broad range of products such as stationary drives, mobile drives, engine systems, personal mobility, vertical lift, stationary hydraulics, mobile hydraulics, vehicle systems, and other industrial products. The company uses its products in various markets such as agriculture, automotive, construction, consumer products energy, general industries and transportation. Gates provides various solutions for power transmission and fluid power including stationary drives and hydraulics, mobile...
-
Product Insights
Shintoshin Prop – Omiya South Gate Office Building – Saitama
The Shintoshin Prop – Omiya South Gate Office Building – Saitama involves the construction of a 58m tall, 29,382.49 m2, 12-story above-ground and one-story below-ground office building on 1.10ha of land at Saitama City, Saitama Prefecture, Japan. Equip yourself with the essential tools needed to make informed and profitable decisions with our Shintoshin Prop – Omiya South Gate Office Building – Saitama report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRAX-628 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRAX-628 in Epilepsy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRAX-628 in Epilepsy Drug Details: PRAX-628 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SI-544 in Psoriatic Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SI-544 in Psoriatic Arthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SI-544 in Psoriatic Arthritis Drug Details: SI-544 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ismidenon in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ismidenon in Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ismidenon in Alzheimer's Disease Drug Details: Ismidenon (AD-101) is under development...